Why did GLSI report zero EPS in recent quarters?

Greenwich Lifesciences Inc (GLSI) has reported zero EPS in recent quarters due to several factors: 1. **Financial Performance**: The company has reported a quarterly adjusted loss of 20 cents per share for the quarter ended September 30, 2024. This loss was primarily due to the fact that the company reported zero revenue for the quarter. Analysts had forecasted a loss of 21 cents per share, but the company's reported loss of 20 cents per share was considered a beat of expectations. 2. **Revenue Situation**: The company's revenue situation has been a concern with no reported revenue for several quarters. For instance, in the fourth quarter of 2023, the company reported zero revenue. In the first quarter of 2024, the company again reported zero revenue. 3. **Cash Situation**: The company's cash position has been under pressure, with a reported decrease in cash from the previous quarter's $6,989,424 to $5,822,367 as of September 30, 2024. This decrease in cash could be a result of the company's inability to generate revenue, which in turn affects its ability to cover expenses and maintain profitability. 4. **Clinical Trial Expenses**: The company is currently developing its breast cancer immunotherapy, GLSI-100, and expanding its Phase III clinical trial, Flamingo-01, into Europe. These clinical trials are likely to be expensive, and the lack of revenue may be offsetting these expenses, leading to a negative EPS. In conclusion, Greenwich Lifesciences Inc's zero EPS in recent quarters can be attributed to a combination of factors including financial performance, revenue situation, cash situation, and clinical trial expenses.